Abstract
ABSTRACTObjective:To study the expression patterns of long noncoding RNA (lncRNA) colon cancer-associated transcript 1 (CCAT1) and the changes in cell proliferation, apoptosis, migration and invasion induced by silencing CCAT1 in bladder cancer cells.Materials and Methods:The expression levels of CCAT1 were determined using realtime quantitative polymerase chain reaction in cancerous tissues and paired normal tissues from 34 patients with bladder cancer. The relationship between clinical characteristics and CCAT1 expression was analyzed. And then we conducted cell experiments. Bladder urothelial carcinoma cell lines T24 and 5637 cells were transfected with CCAT1 small interfering RNA (siRNA) or scramble siRNA. Cell proliferation and apoptosis changes were determined using a Cell Counting Kit-8 (CCK-8) assay and a flow cytometry assay. Migration and invasion changes were measured using a wound healing assay and a trans-well assay. microRNAs (miRNAs) were predicted by Starbase 2.0, and their differential expression levels were studied.Results:CCAT1 was significantly upregulated in bladder cancer (P < 0.05). CCAT1 upregulation was positively related to tumor stage (P = 0.004), tumor grade (P = 0.001) and tumor size (P = 0.042). Cell proliferation, migration and invasion were promoted by abnormally expressed CCAT1. miRNAs miR-181b-5p, miR-152-3p, miR-24-3p, miR-148a-3p and miR-490-3p were potentially related to the aforementioned functions of CCAT1.Conclusion:CCAT1 plays an oncogenic role in urothelial carcinoma of the bladder. In addition, CCAT1 may be a potential therapeutic target in this cancer.
Highlights
Bladder cancer is the ninth most common cancer worldwide [1]
cancer-associated transcript 1 (CCAT1) is upregulated in bladder cancer tissues First, we investigated whether CCAT1 was dysregulated in bladder cancer tissues relative to its expression in adjacent healthy cells
We investigated the relationship between increased CCAT1 expression levels and clinical characteristics in the 34 bladder cancer cases to determine whether CCAT1 expression is related to clinical features (Table-1)
Summary
Bladder cancer is the ninth most common cancer worldwide [1]. Most malignant bladder tumors are urothelial carcinomas evolved from the urothelium. 40% of patients with bladder cancer have experienced multiple recurrences, significantly impacting their life quality [2]. Muscle invasive or high-grade bladder tumors are more aggressive relatively [3]. Tumors greater than 3cm comprise a risk factor of recurrence and progression [4]. The mortality of bladder cancer has not changed markedly despite recent advances ibju | lncRNA CCAT1 promotes bladder cancer in its early detection [5]. It is necessary to delineate the molecular mechanisms involved in the development of bladder cancer to find potentially novel and important diagnostic markers and therapeutic targets
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
